Supplementary figures
Supplementary Figure 1: The employed sequences. Shown are the AM132 and random oligonucleotides that were employed in this study, as well as the synthetic miR-132 and complementary 3'-UTR sequences that were tested by SPR measurements (m=methyl group; *on the sequence notes phosphorothioate protection; starred structure notes the binding site location.
Supplementary Figure 2:
AM132 increases muscle, but not brain levels of both the stress-induced splicing factor SC35 and the epigenetic regulator Sirt1, whereas LPS elevates SC35 in the brain. Following AM132 treatment, an in increase in SC35 expression was observed in (a) muscle with AM132 treatment and (b) brain with LPS exposure, but no change in brain with AM132 treatment. Note these changes are in congruence with changes in miR-132 in these systems. (c) Sirt1 expression increased with AM132 treatment as found through SPR analysis.
Supplementary Figure 3: Segregation of miR profile samples as per group.
Shown is PCA analysis of all of the miRs identified as differentially expressed in cortical tissues from mice belonging to the LPS and AM132 treated groups. Note that both AM132 treated and LPS-exposed samples were well segregated from their respective controls, with AM132 segregation resolution being better than LPS treatment group.
Supplementary Figure 4:
CholinomiRs expression in the frontal cortex. TargetScan predicted miRs targeting cholinergic transcripts were largely upregulated following LPS exposure but were not changed under AM132 treatment, suggesting LPS-induced suppression of stress and inflammation-inducible cholinergic signaling and inverse AM132-mediated potentiation of cholinergic reactions in the brain. 
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